

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	6/28/1989	
Gender:	Male	
Patient Identifiers:	01234567890ABCD, 012345	
Visit Number (FIN):	01234567890ABCD	
Collection Date:	00/00/0000 00:00	

ARUP test code 3005882		
Fam. Dysautonomia (ELP1), Specimen	Whole Blood	
Fam. Dysautonomia (ELP1), Allele 1	Negative	
Fam. Dysautonomia (ELP1), Allele 2	Negative	
Fam. Dysautonomia (ELP1), Interp	See Note Indication for testing: Carrier screening or diagnostic testing for familial dysautonomia.	
	Negative: This sample is negative for the two variants tested in the ELP1 gene. If this is an asymptomatic individual of Ashkenazi Jewish descent, his/her risk of being a carrier of familial dysautonomia is reduced from 1 in 32 to approximately 1 in 3,100. This result has been reviewed and approved by	

Dysautonomia, Familial (ELP1), 2 Variants ARUP test code 3005882

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2767 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director



BACKGROUND INFORMATION: Dysautonomia, Familial (ELP1), 2 Variants

CHARACTERISTICS: Familial dysautonomia is a debilitating disease caused by abnormal development and survival of sensory, sympathetic, and parasympathetic neurons. Symptoms include gastrointestinal dysfunction, vomiting and autonomic crises, recurrent pneumonia, altered sensitivity to pain and temperature, scoliosis, and cardiovascular instability. Other characteristics include infantile hypotonia, deteriorating wide-based ataxic gait, and decreased life expectancy. INCIDENCE: 1 in 3,600 Ashkenazi Jewish individuals. INHERITANCE: Autosomal recessive. CAUSE: ELP1 pathogenic variants. VARIANTS TESTED: p.R696P (c.2087G>C) and c.2204+6T>C. CLINICAL SENSITIVITY: 99 percent in Ashkenazi Jewish individuals, unknown in other ethnicities. METHODOLOGY: Polymerase chain reaction (PCR) and fluorescence monitoring. ANALYTICAL SENSITIVITY AND SPECIFICITY: 99 percent. LIMITATIONS: Variants other than p.R696P (c.2087G>C) and c.2204+6T>C will not be detected. Diagnostic errors can occur due to rare sequence variations.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

VERIFIED/REPORTED DATES					
Procedure	Accession	Collected	Received	Verified/Reported	
Fam. Dysautonomia (ELP1), Specimen	23-334-127516	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Fam. Dysautonomia (ELP1), Allele 1	23-334-127516	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Fam. Dysautonomia (ELP1), Allele 2	23-334-127516	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Fam. Dysautonomia (ELP1), Interp	23-334-127516	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 23-334-127516 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 2 of 2 | Printed: 1/31/2024 3:24:01 PM 4848